Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Alto Neuroscience Inc (NYSE: ANRO) was $4.28 for the day, down -1.15% from the previous closing price of $4.33. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 0.12 million shares were traded. ANRO stock price reached its highest trading level at $4.5 during the session, while it also had its lowest trading level at $4.28.
Ratios:
Our analysis of ANRO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.09 and its Current Ratio is at 13.09. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on October 23, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $29 previously.
On September 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $29.Wedbush initiated its Outperform rating on September 03, 2024, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 09 ’24 when Savitz Adam bought 12,069 shares for $12.60 per share. The transaction valued at 152,085 led to the insider holds 36,920 shares of the business.
Savitz Adam bought 2,931 shares of ANRO for $38,748 on Jul 10 ’24. The CHIEF MEDICAL OFFICER now owns 39,851 shares after completing the transaction at $13.22 per share. On Mar 28 ’24, another insider, Smith Nicholas Conrad, who serves as the CHIEF FINANCIAL OFFICER of the company, bought 6,150 shares for $16.36 each. As a result, the insider paid 100,628 and bolstered with 26,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANRO now has a Market Capitalization of 115432464 and an Enterprise Value of -51505960.
Stock Price History:
Over the past 52 weeks, ANRO has reached a high of $24.00, while it has fallen to a 52-week low of $3.61. The 50-Day Moving Average of the stock is -47.89%, while the 200-Day Moving Average is calculated to be -64.03%.
Shares Statistics:
ANRO traded an average of 771.62K shares per day over the past three months and 391420 shares per day over the past ten days. A total of 26.88M shares are outstanding, with a floating share count of 21.99M. Insiders hold about 18.48% of the company’s shares, while institutions hold 80.10% stake in the company. Shares short for ANRO as of 1731628800 were 4661129 with a Short Ratio of 6.04, compared to 1728950400 on 5351105. Therefore, it implies a Short% of Shares Outstanding of 4661129 and a Short% of Float of 21.94.
